


## SPR719

Cat. No.:	HY-12930		
CAS No.:	1384984-18-2		
Molecular Formula:	C <sub>21</sub> H <sub>25</sub> FN <sub>6</sub> O <sub>3</sub>		
Molecular Weight:	428.46		
Target:	Topoisomerase; Bacterial		
Pathway:	Cell Cycle/DNA Damage; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 20 mg/mL (46.68 mM; ultrasonic and adjust pH to 2 with HCl)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3339 mL	11.6697 mL	23.3394 mL
5 mM	0.4668 mL	2.3339 mL	4.6679 mL
10 mM	0.2334 mL	1.1670 mL	2.3339 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SPR719 (VXc-486) is a gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 µg/ml and 0.08 to 5.48 µg/ml, respectively<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

gyrase B<sup>[1]</sup>

### CUSTOMER VALIDATION

- Cell. 2021 Aug 19;184(17):4579-4592.e24.
- Antimicrob Agents Chemother. 2023 Jan 23:e0145922.
- Antimicrob Agents Chemother. 2021 May 17;AAC.00676-21.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. *Antimicrob Agents Chemother.* 2015 Mar;59(3):1455-65.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA